Nasdaq

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...

ProofPilot Announces 2nd CORE Symposium, Gathering Pharma and Biotech Leaders to Tackle Clinical Operations' Toughest Challenges

ProofPilot, the platform purpose-built to make clinical trials simple and predictable for study stakeholders, today announced the return of the CORE Symposium, its invite-only event for pharma and ...

electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD

ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness ...
Seeking Alpha

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures “It is critically important to conduct long-term, real-world studies like CORE ...